Related Experiment Video
Updated: Dec 27, 2025
03:47
A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
Published on: October 25, 2024
558
Diffuse sclerosing osteomyelitis: a case series and literature review
Jasveen Matharu1, Hazel Taylor1, Chris Sproat2
1Oral Surgery, Specialty Dentist, Guys Dental Hospital, Oral Surgery Department, London, UK.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
|February 28, 2020
Summary
Oral bisphosphonates, such as alendronic acid, show promise in managing diffuse sclerosing osteomyelitis (DSO) of the mandible. This treatment provided symptom relief for most patients, offering a potential new therapeutic avenue for this chronic inflammatory condition.
Area of Science:
- Oral medicine
- Pharmacology
- Inflammatory diseases
Background:
- Diffuse sclerosing osteomyelitis (DSO) is a poorly understood chronic inflammatory condition.
- Etiology and optimal treatment for DSO remain unclear.
- Bisphosphonates are a class of drugs used to treat bone density loss.
Observation:
- A retrospective analysis of 11 patients with mandibular DSO was conducted.
- Eight patients received oral bisphosphonates (alendronic acid) after other treatments failed.
- Data on treatment modalities and outcomes were collected.
Findings:
- All 8 patients on alendronic acid reported symptom improvement or resolution within 72 hours.
- Five patients experienced improved symptom control compared to previous treatments.
- Three patients discontinued medication due to side effects.
Implications:
- Oral bisphosphonates may offer prolonged symptom relief for DSO patients.
- This suggests a potential role for bisphosphonates in DSO treatment.
- Further research is needed to determine optimal regimens and understand DSO pathophysiology.
